Other languages Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
126.7 ^USD	-1.66%		+8.15%	+31.35%

Mar. 21	FDA greenlights Italfarmaco's drug for rare muscular dystrophy	RE
Mar. 12	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FDA greenlights Italfarmaco's drug for rare muscular dystrophy	Mar. 21
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	Mar. 12
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	Mar. 07
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	Feb. 29
Sarepta Therapeutics anuncia convocatoria de solicitudes para el 7.º Route 79 anual, el Programa de Becas de Duchenne	Feb. 29
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	Feb. 28
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Prices for new US drugs rose 35% in 2023, more than the previous year	Feb. 23
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 16
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16
Sector Update: Health Care	Feb. 16
Sarepta Therapeutics Says FDA Grants Priority Review to Efficacy Supplement to Elevidys' BLA to Expand its Indication	Feb. 16
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data	Feb. 16
US FDA to review Sarepta's Duchenne gene therapy for traditional approval	Feb. 16
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication	Feb. 16
Wegovy packing supplier Catalent lays off 300 workers	Feb. 14
Prévisions Roche: chiffre d'affaires annuel autour de 59 milliards de francs	Jan. 31
Sarepta says its experimental Duchenne drug more effective than older medicine	Jan. 29
Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51	Jan. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Other languages

Filters